The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97)

Haematologica

Volumn 96, Issue 6, 2011, Pages 854-862

  Escherich, Gabriele ^a   Tröger, Anja ^c   Göbel, Ulrich ^c   Graubner, Ulrike ^d   Pekrun, Arnulf ^e   Jorch, Norbert ^f   Kaspers, Gjl ^g   Zimmermann, Martin ^h   Stadt, Udo Zur ^b   Kazemier, Karin ⁱ   Pieters, Rob ⁱ   den Boer, Monique L ⁱ   Horstmann, Martin ^a,b   Janka, Gritta E ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Research Institute Children's Cancer Center   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Prof Hess Kinderklinik   (Germany)

^f Gilead Children's Hospital   (Germany)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Childhood; In vitro drug testing; Minimal residual disease; Risk adapted treatment

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG SENSITIVITY; FOLLOW UP; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; PROGNOSIS; RISK ASSESSMENT; T CELL LEUKEMIA; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INFANT; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79958036116     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.039735     Document Type: Article

References (35)

1. Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Does-van den Berg A, van Wering ER, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338(8764):399-403.
2. Kaspers GJ, Pieters R, Van Zantwijk CH, De Laat PA, De Waal FC, Van Wering ER, et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer. 1991;64 (3): 469-74.
3. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90(7): 2723-9.
4. Kaspers GL, Veerman AJ, Pieters R, van Zantwijk I, Klumper E, Hählen K, et al. In vitro cytotoxicity of mitoxantrone, dauno - rubicin and doxorubicin in untreated childhood acute leukemia. Leukemia. 1994; 8(1):24-9.
5. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352 (9154):1731-8.
6. Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, Dalton V, et al; Dana- Farber Cancer Institute ALL Consortium. Quantitative analysis of minimal residual disease predicts relapse in children with Blineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007;110(5):1607-11.
7. zur Stadt U, Harms DO, Schlüter S, Schrappe M, Goebel U, Spaar H, et al. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leukemia. 2001; 15(2):283-5.
8. Silverman LB, Sallan SE. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol. 2003;10(4):290-6.
9. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia. 1998; 12(9):1344-8.
10. Ramakers-van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for Lasparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96(3): 1094-9.
11. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood. 1997;89(8):2959-65.
12. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, et al. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood. 1998;92(1):259-66.
13. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;122(3):376-85.
14. Styczynski J, Wysocki M. Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol. 2004; 22(5):963-4.
15. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Padiatr. 1999;211(4):233-8.
16. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D, et al. Patient stratification based on prednisolone- vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21 (17): 3262-8.
17. Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, Mullighan CG, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. 2010;115(23): 4657-63.
18. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-14.
19. De Haas V, Kaspers GJ, Oosten L, Bresters D, Pieters R, Van Der Velden VH, et al. Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia? Br J Haematol. 2002;118(4):1190-200.
20. Schmiegelow K, Nyvold C, Seyfarth J, Pieters R, Rottier MM, Knabe N, et al. Postinduction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. Leukemia. 2001;15 (7):1066-71.
21. Lönnerholm G, Thörn I, Sundström C, Frost BM, Abrahamsson J, Behrendtz M, et al. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of therapy in childhood acute lymphoblastic leukemia. Leuk Res. 2009; 33(1):46-53.
22. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer- Grumayer ER, et al; European Study Group on MRD detection in ALL (ESG-MRDALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-11.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
24. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY, Wiley; 2002.
25. Andersen PK, Borch-Johnsen K, Deckert T, Green A, Hougaard P, Keiding N, Kreiner S. A Cox regression model for the relative mortality and its application to diabetes mellitus survival data. Biometrics. 1985; 41 (4):921-32.
26. Graubner UB, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G, et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Ped Blood Cancer. 2008;50 (2): 259-63.
27. Farber S, Diamond L, Mercer R, Sylvester R, Wolff J. Temporary remissions in acute leukemia in children produced by folic and antagonist 4-aminopteroyl-glutamic acid (Aminopterin). N Engl J Med. 1948; 238: 787-93.
28. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2): 265-84.
29. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, et al. Long term results of St Judes total therapy studies 11,12,13A,13B and 14 in childhood acute lymphoblastic leukemia. Leukemia. 2010; 24(2):371-82.
30. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, et al. Long term results of Dana-Farber Cancer Institute ALL consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leu - kemia. 2010;24 (2):320-34.
31. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, et al; Children's Oncology Group. Long term results of the Children's Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002. A Childrens Oncology Group report. Leukemia. 2010; 24(2): 285-97.
32. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Söderhäll S, Taskinen M; Nordic Society of Paediatric Haematology and Oncology. Long term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblstic leukemia. Leukemia. 2010;24(2):345-54.
33. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, et al. Long-Term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukaemia. J Clin Oncol. 2005; 23(28):7161-7.
34. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli asparaginase with Erwinia asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-9.
35. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, et al. Asparaginase antibody and asparaginase activity in children with higer risk acute lymphoblastic leukaemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217-26.